Relmacabtagene Autoleucel
Cell therapy targets CD19
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT06414135 | Jun 2024 → May 2025 overdue | systemic sclerosis | Liangjing Lu | Recruiting | No outcome recorded |
| Phase 1 | NCT06297408 | Mar 2024 → May 2025 | systemic lupus erythematosus | Shanghai Ming Ju Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05765006 | Feb 2023 → Dec 2024 | systemic lupus erythematosus | Shanghai Ming Ju Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05727683 | Apr 2022 → Oct 2023 | acute lymphoblastic leukemia | Shanghai Ming Ju Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05259813 | Feb 2022 → Jan 2023 | B-cell chronic lymphocytic leukemia | Shanghai Ming Ju Biotechnology Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04812691 | Jul 2020 → Jun 2021 | diffuse large B-cell lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03355859 | Jan 2018 → Dec 2019 | non-Hodgkin lymphoma | Zhao Weili | Unknown | No outcome recorded |
| Phase 1 | NCT03344367 | Nov 2017 → Oct 2019 | non-Hodgkin lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07326371 | Mar 2026 → Jul 2027 expected | diffuse large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07077512 | Sep 2025 → Jan 2027 expected | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06479356 | Aug 2024 → Apr 2025 overdue | large B-cell lymphoma, non-Hodgkin lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06365671 | Apr 2024 → Apr 2026 overdue | B-cell non-Hodgkin lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06876688 | Nov 2023 → Nov 2028 expected | lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06093841 | Nov 2023 → Jan 2024 overdue | high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06149169 | Aug 2023 → Oct 2024 | diffuse large B-cell lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05590221 | Jan 2023 → Feb 2024 | large B-cell lymphoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04718883 | Jan 2021 → Oct 2023 overdue | mantle cell lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04089215 | Jun 2019 → Sep 2021 | diffuse large B-cell lymphoma, follicular lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05814848 | Jun 2023 → Mar 2028 expected | B-cell non-Hodgkin lymphoma | Changhai Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05806580 | May 2023 → May 2027 expected | B-cell non-Hodgkin lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07198464 | Oct 2025 → Oct 2029 expected | primary central nervous system lymphoma | Zhengzhou University | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05370547 Background | May 2022 → Jun 2024 | non-Hodgkin lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Relmacabtagene autoleucel | “Relmacabtagene autoleucel (relma-cel) is the second anti-CD19 CAR-T product approved for marketing by the National Medical Products Administration (NMPA) in China” PMID 40386685 ↗ Apr 202510“This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.” NCT06149169 ↗ “Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.” PMID 33382529 ↗ Dec 2020 “JWCAR029 (Relmacabtagene Autoleucel)” NCT05259813 ↗ |
| Known as | Carteyva | “Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial.” PMID 36053875 ↗ Sep 2022 |
| Known as | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04718883 ↗ |
| Known as | JWCAR029 | “Relma-cel (JWCAR029), an anti-CD19 product produced with a commercial-ready process in China, was evaluated in the first prospective, single-arm, multicenter, pivotal study of...” PMID 33382529 ↗ Dec 20205“A Phase I Open, Single-arm Study of JWCAR029 (CD19-targeted Chimeric Antigen Receptor T Cells) for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia” NCT05727683 ↗ |
| Known as | relma-cel | “This is a prospective, open-label, multicenter, single-arm trial, assessed the efficacy and safety of JWCAR029(relma-cel) as part of first-line therapy after an incomplete...” NCT05590221 ↗11“A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10\^6 for Relma-cel or 2 × 10\^6/kg for Axi-cel.” NCT05370547 ↗ “Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.” PMID 33382529 ↗ Dec 2020 “An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed and Refractory (R/R) LBCL” NCT06149169 ↗ “Relmacabtagene autoleucel (relma-cel)” NCT06365671 ↗ “Relmacabtagene autoleucel (relma-cel)” NCT07326371 ↗ |
| Action | Deplete | “In all patients treated with relma-cel, CD19+ B cells in peripheral blood were almost completely depleted within 11-15 days and gradually recovered within 2-6 months.” PMID 40386685 ↗ Apr 2025 |
| Modality | Cell therapy | “CD19-targeted Chimeric Antigen Receptor (CAR) T Cells” NCT03355859 ↗ |
| Route | Intravenous | “one dose treatment with JWCAR029 by intravenous (IV) injection” NCT03344367 ↗ |
| Target | CD19 | “CD19-targeted chimeric antigen receptor” NCT03355859 ↗ |